Schrödinger achieved total revenue of $59.6 million in Q1 2025, representing a 63% increase compared to the same period last year, with software revenue growing 46% to $48.8 million.
Schrödinger presented preclinical data for SGR-3515, a Wee1/Myt1 co-inhibitor showing superior anti-tumor activity compared to monotherapy inhibitors, with optimized dosing schedules that preserve efficacy while minimizing side effects.